Videos

Misinformation and disinformation are widespread and having adverse effects on individuals’ health decisions. How can we address the problem?

Experts in psychiatry discuss the future of ADHD management as well as challenges when approaching treatment of adult ADHD.

Stephen Faraone, PhD; Theresa Cerulli, MD; Craig Chepke, MD, FAPA; and Andrew J. Cutler, MD, discuss efficacy and safety of treatment options in adults with ADHD.

Craig Chepke, MD, FAPA, and Andrew J. Cutler, MD, discuss unmet needs in adults with ADHD.

"We ate, and talked, and went to bed, And slept. It was a miracle."

"Oceans rise, empires fall, we have seen each other through it all..."

How can we help others in September, National Suicide Prevention Month?

Our panel concludes with their final thoughts on using DTx and PDT management.

Three doctors discuss whether PDTs should be covered as a pharmacy benefit or medical benefit.

Drs Podesta and Aungst elaborate on DTx and PDT access and the impact these therapeutics can have in the behavioral health treatment landscape.

"If I could only live at the pitch that is near madness..."

Drs Stephen Faraone, Theresa Cerulli, Craig Chepke, and Andrew J. Cutler discuss how to diagnose adults with ADHD based on patient presentation.

Experts in ADHD compare the diagnosis and management of ADHD in adults and children.

Stephen Faraone, PhD; Theresa Cerulli, MD; Craig Chepke, MD, FAPA; and Andrew J. Cutler, MD, discuss the prevalence of adult ADHD.

What are the best characteristics of psychiatry?

A panel of specialists focus on how real-world evidence affects the use and acceptance of digital therapeutics and prescription digital therapeutics, as well as FDA approvals.

Scott Whittle, MD, and Arwen Podesta, MD, confer about cost savings from digital therapeutics and prescription digital therapeutics from payer and provider perspectives.

"...Then twenty years swing by and I’m riffing chords on my father’s old D’Angelico, Grappelli’s photo clipped to the stand, an image captured the night he owned the ballroom stage, me on the dance floor..."

Psychiatrists and mental health clinicians need to take better care of themselves. The best way to do so? Love.

Drs Whittle and Podesta discuss the durability and stability of DTx and PDT treatment.

Medical authorities detail how PDTs are compared with other, more conventional treatment modalities in behavioral health.

"I'm thinking about how good it is to have been sick, to have been turned inside out..."

Why did it take Freud so long to leave Nazi-invaded Austria? Much like Freud, we may not understand all the risks around us.

Treating both cancer and mental health can be difficult. Here's why it's important to do so collaboratively.

CBD and THC? What's the difference and why does it matter?

Scott Whittle, MD, uses his knowledge and experiences as a payer—with the help of the other panelists—to explain how the FDA uses gathered evidence to make decisions on approvals for PDTs.

Clinicians, pharmacists, and payers discuss how DTx and PDTs are monitored—for access, efficacy, adherence, and more.

"You think you’re too small to make a difference?"

The resistance against "magic mushrooms"—is it justified?

Is it time to retire?